Your session is about to expire
← Back to Search
Interferon
Ropeginterferon Alfa-2B for Myelofibrosis
Phase 2
Waitlist Available
Led By Jeanne Palmer
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No prior treatment for myelofibrosis (for cohort 1 only)
For cohort 1: early stage MF without currently available treatment options
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial looks at P1101 to treat patients with myelofibrosis. P1101 may help the body's natural response and slow the growth of myelofibrosis.
Who is the study for?
This trial is for patients with myelofibrosis who have symptoms like anemia and enlarged spleen, and are in different stages of the disease. Some should not have had treatment before, while others may have tried a drug called ruxolitinib without success. Participants need to be relatively healthy otherwise, able to answer questions about their health, and willing to provide blood samples.Check my eligibility
What is being tested?
The trial is testing P1101 (PEG-proline-interferon alpha-2b), which might help the body fight myelofibrosis better by slowing its growth. The study includes tests on how this treatment affects patients' quality of life and tracks changes through lab biomarker analysis.See study design
What are the potential side effects?
While specific side effects for PEG-proline-interferon alpha-2b aren't listed here, similar drugs can cause flu-like symptoms, fatigue, mood changes or depression, irritation at injection site, and sometimes changes in blood counts leading to increased risk of infections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have not received any treatment for myelofibrosis.
Select...
I have early stage mycosis fungoides with no treatment options left.
Select...
My kidneys are functioning well.
Select...
My spleen is enlarged due to myelofibrosis.
Select...
I have intermediate-2 or high-risk myelofibrosis and cannot take or did not respond to ruxolitinib.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I have been diagnosed with myelofibrosis according to WHO standards.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Best overall response (CR, PR, or CI) as determined by International Working Group Criteria
Secondary outcome measures
Incidence of adverse events, as measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4)
Survival time
Other outcome measures
Changes in patient-reported symptoms and QOL as measured by MPN-SAF
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (PEG-proline-interferon alpha-2b)Experimental Treatment3 Interventions
Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,242 Previous Clinical Trials
3,773,738 Total Patients Enrolled
7 Trials studying Primary Myelofibrosis
424 Patients Enrolled for Primary Myelofibrosis
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,352 Total Patients Enrolled
69 Trials studying Primary Myelofibrosis
6,830 Patients Enrolled for Primary Myelofibrosis
Jeanne PalmerPrincipal InvestigatorMayo Clinic
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not received any treatment for myelofibrosis.I have early stage mycosis fungoides with no treatment options left.I am in cohort 1 and have a high or intermediate-2 risk disease.I am currently breastfeeding.I am of childbearing age and not using birth control.My kidneys are functioning well.I had a heart attack less than 6 months ago or need ongoing treatment for heart failure.My spleen is enlarged due to myelofibrosis.I have intermediate-2 or high-risk myelofibrosis and cannot take or did not respond to ruxolitinib.I can take care of myself and am up and about more than half of my waking hours.I have had radiation treatment to my spleen within the last 3 months.I have moderate to severe numbness, tingling, or pain in my hands or feet.I am immunocompromised or HIV positive and on antiretroviral therapy.I have had a stem cell transplant before.I haven't had chemotherapy or radiation in the last 2 weeks.I do not have any other active cancer.I have been diagnosed with myelofibrosis according to WHO standards.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (PEG-proline-interferon alpha-2b)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger